TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02966522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01235858

Intervention type: PROCEDURE
Group type: OTHER
Intervention: wearing of sterile gowns
Description: Anesthesiologists wearing sterile gown for epidural insertion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No gown
Description: Anesthesiologists not wearing sterile gown for epidural insertion
Study: NCT05332080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation via application on cell phone
Description: Realization of rehabilitation through content in an app they received advice on self-care and the type of exercises to do. The program consisted of hydrotherapy, mobility exercises, muscle strengthening, and activities to improve wrist and hand function, with planned goals.
Study: NCT04496778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)
Description: Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity
Study: NCT02987413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal stem cells (MSCs)
Description: 2 intrathecal autologous MSCs infusions (1x10\^8 cells) will be performed, escalated from 30 days apart
Study: NCT02268838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Study: NCT04496778

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low level laser therapy ( laser acupuncture combined with nasal laser irradiation)
Description: Cold Laser Therapy Watch (Laser Watch- 650 nm) combines acupuncture and nasal cavity for external blood irradiation. Laser watch with 10 laser beams - is applied to the left wrist.~Nasal Probe with 2 laser beams - is applied to the nose cavity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: 3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: 3 d/week for 45 to 60 minutes per session for 3 months. started by 40%-50% Heart Rate Reserve (determined by using a walking treadmill exercise test) during the first 6 weeks increasing gradually up to 50%-70% Heart Rate Reserve
Study: NCT02222285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Food : Vayarin_005
Study: NCT02268838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007 matching placebo
Study: NCT03291444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cells
Description: After pretreatment, chimeric antigen receptor T cells will be transfused.
Study: NCT02222285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Food : Vayarin_005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03291444

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chimeric antigen receptor T cells
Description: After pretreatment, chimeric antigen receptor T cells will be transfused.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide specific dendritic cell
Description: After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
Study: NCT01881308

Intervention type: DRUG
Group type: OTHER
Intervention: TNF inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF inhibitors
Study: NCT00254722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow precursor cell harvest and transplant
Description: Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury
Study: NCT02222285

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03852953

Intervention type: OTHER
Intervention: Screening
Description: Invited or attended BreastScreen Norway
Study: NCT01974518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab and Cyclophosphamide IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab and Cyclophosphamide IV
Study: NCT03792841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
Study: NCT00808210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous repeating dose
Study: NCT01881308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF inhibitors

Intervention type: DRUG
Group type: OTHER
Intervention: Synthetic DMARD(s)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic DMARD(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic DMARD(s)

Intervention type: DRUG
Group type: OTHER
Intervention: Co-medication: Synthetic DMARDs
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-medication: Synthetic DMARDs
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-medication: Synthetic DMARDs
Description: Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
Study: NCT00748436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: (24mg tablet Betahistine + placebo tablet) BID per os 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betahistine dihydrochloride
Description: (24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: (placebo tablet + placebo tablet) BID per os 12 weeks
Study: NCT01318187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1 gr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1 gr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: 0.1mg/kg intravenous in 100 ml serum physiologic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: 0.1mg/kg intravenous in 100 ml serum physiologic
Study: NCT03792841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acapatamab
Description: Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Combined with acapatamab for investigational treatment of mCRPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Prophylaxis for acapatamab-related cytokine release syndrome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytochrome P450 (CYP) Cocktail
Description: Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
Study: NCT03198481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Centered Counseling Video
Description: Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Counseling Video
Description: Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
Study: NCT03933319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
Study: NCT02972151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment of TCM
Description: Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant treatment
Description: Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
Study: NCT05747833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children Preparation With a Toy IV Catheter Before Peripheral Cannula application
Description: THE EFFECT OF PROCESSING PREPARATION WITH A TOY IV CATHETER BEFORE PERIPHERAL CANNULA APPLICATION ON CHILDREN'S PAIN, FEAR and EMOTIONAL INDICATORS
Study: NCT04124978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mandibular advancement device
Description: use of prefabricated adjustable mandibular advancement device to improve OSA
Study: NCT02039583

Intervention type: OTHER
Intervention: Smoke-free legislation
Description: The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
Study: NCT01901211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming Intervention
Description: The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
Study: NCT04444752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-201
Description: CBP-201 subcutaneous(SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous(SC) injection
Study: NCT02225028

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Counseling
Description: Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
Study: NCT03137485

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional open lumbar discectomy
Description: Removal of single level lumbar disc herniation through conventional discectomy.
Study: NCT01318187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1 gr intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: intravenous 1 gr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg intravenous
Study: NCT00804947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous busulfan and melphalan
Description: BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
Study: NCT01470755

Intervention type: DRUG
Group type: OTHER
Intervention: salbutamol
Description: Metered dose inhaler, 100µg+300µg per puff, administered one day
Study: NCT03137485

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Endoscopic Translaminar lumbar discectomy.
Description: Removal of single level Lumbar disc herniation using endoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Easy Go system Endoscopy
Description: This system will be used to remove herniated disc in endoscopic group
Study: NCT01470755

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol - dose2
Description: Metered dose inhaler, 100µg+500µg per puff, administered one day

Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol -dose3
Description: Metered dose inhaler, 200µg+600µg per puff, administered one day

Intervention type: DRUG
Group type: OTHER
Intervention: salbutamol -dose4
Description: Metered dose inhaler, 200µg+200µg per puff, administered one day
Study: NCT06532955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis using Microsure Motion Stabilizer
Description: The robot-assisted LVA is performed using the Microsure Motion Stabilizer, a telemanipulation tool that stabilizes a surgeon's movement during open microsurgical operations on extremities, specifically on veins and nerves that are close to the skin.~The surgeon controls a joystick, which directly copies the surgeon's movements in real-time to an instrument held by the device. The device's software scales down the motions and filters out tremor. Surgical technique and method of treatment are identical to conventional microsurgery. The device is equipped with genuine microsurgical instruments and is compatible with existing surgical microscopes. Instead of holding the instrument directly in hand, which is limited in precision and dexterity, the surgeon operates while the instrument's movements are stabilized. The modular design allows the surgeon to decide what level of manipulation assistance is required during a certain procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphaticovenous anastomosis (manual)
Description: Lymphaticovenous anastomosis (LVA) involves connecting a lymphatic vessel to an adjacent vein of similar size, thereby facilitating the outflow of lymphatic fluid in patients suffering from secondary lymphedema
Study: NCT01531868

Intervention type: OTHER
Group type: OTHER
Intervention: Video
Description: Video of physician
Study: NCT04297540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS group
Description: Active anodal-tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 1.5mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
Study: NCT04297540

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS group
Description: Sham -tDCS will be delivered over the cerebellum for 8 sessions in two weeks. tDCS will be delivered via a battery driven direct current stimulator. Saline-soaked sponges electrodes will be placed on the cerebellar vermis (anodal electrode) and over the right buccinator muscle (reference electrode). Stimulation intensity will be set at 1.5 mA but the current will be applied for 30 sec. The intensity of the stimulation will be gradually increase in order to reach the 1.5 mA with a ramping-up phase of 15 sec. Similarly, a ramping-down phase of 15 sec will gradually decrease the intensity before the end of the stimulation. The duration of the 0mA stimulation will be 20 minutes. Soon after the end of the stimulation, the virtual reality training will be performed. The virtual reality training will took place in a child-friendly scenario. It will comprise a total of 80 trials, during which participants will be asked to compete with some avatars in order to activate and to win some objects.
Study: NCT01559402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP and 100% oxygen
Description: During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP and 31% oxygen
Description: During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No CPAP and 100% oxygen
Description: This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
Study: NCT04318340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapered applicator
Description: An applicator inserted in 2 steps that tapers at the distal vagina

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard applicator
Description: A 2.6 cm standard applicator is inserted and sized up to a standard 3 cm applicator if tolerable.
Study: NCT03408912

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FFR
Description: FFR from CMR compared to invasive FFR
Study: NCT01752192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation programme
Description: Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
Study: NCT00647712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium Extended-Release Tablets 500 mg
Description: 500mg, single dose fasting
Study: NCT01531868

Intervention type: OTHER
Group type: OTHER
Intervention: Video
Description: Video of physician

Intervention type: OTHER
Group type: OTHER
Intervention: Video
Description: Video of physician

Intervention type: OTHER
Group type: OTHER
Intervention: Video
Description: Video of physician
Study: NCT00647712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote ER® Tablets 500 mg
Description: 500mg, single dose fasting
Study: NCT01574300

Intervention type: OTHER
Intervention: therapeutic interventions
Description: All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics